GLP-1 / metabolic
Tesofensine
Research chemicalNS2330 · Triple monoamine reuptake inhibitor
Investigational brain-acting appetite suppressant (not a peptide).
What it is
A small-molecule triple monoamine reuptake inhibitor originally developed for neurodegenerative disease, repurposed for obesity.
How it works
Inhibits reuptake of serotonin, norepinephrine and dopamine, raising their central levels to suppress appetite.
Studied for
Obesity / weight loss.
Regulatory status
Investigational; not FDA-approved.
Safety
Monoaminergic effects raise concern for higher heart rate, blood pressure, and mood/sleep changes.
What the community reports about Tesofensine
Aggregated from real community discussions across social platforms and forums. Anecdotal and self-reported — not causal, not medical advice.
The stimulant-adjacent appetite suppressant. Tesofensine is a SNDRI — it raises serotonin, norepinephrine and dopamine — which suppresses appetite (commenters liken it to "antidepressants but suppressing appetite," or "adderall + antidepressants") and adds a cognitive / sense-of-well-being lift.
- Central SNDRI appetite suppressant with a cognitive/mood lift
- Oral appetite-suppressant + nootropic used to break GLP-1 stalls
- Effect can fade after ~2 weeks; constipation; tolerance/'chasing the high'
Aggregated from public discussions and community forums, synthesized into themes and counts. Anecdotal and self-reported — not causal, not evidence a compound is safe or effective, not medical advice, and not a recommendation to use. No dosing shown.
Educational information only — not medical advice, and not a recommendation to use any compound. Many peptides here are not approved for human use; legal status and evidence quality vary and are noted above. This page contains no dosing information. Consult a qualified clinician before making any health decision.